Develops live biotherapeutic products for inflammatory and immune diseases.
Jun 2026Revenue $1.88M/yrExpenses $85.9M/yr
No trendCash runway ≈ 4 months from Jun 2026
Figures by year
When will Seres Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $1.88M and expenses $85.9M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $789K | $94.8M | −$94.0M |
| Dec 2024 | $0.00 | $121M | −$121M |
| Dec 2023 | $0.00 | $195M | −$195M |
| Dec 2022 | $7.13M | $187M | −$180M |
| Dec 2021 | $145M | $209M | −$64.5M |
| Dec 2020 | $33.2M | $121M | −$88.1M |
| Dec 2019 | $34.5M | $106M | −$71.9M |
| Dec 2018 | $28.3M | $129M | −$100M |
| Dec 2017 | $32.1M | $123M | −$91.4M |
| Dec 2016 | $21.8M | $115M | −$92.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.